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Post kala-azar dermal leishmaniasis: Burden,
diagnosis and treatment challenges
V. Ramesh
Safdarjung Hospital, New Delhi, India
Abstract: Post-kala-azar dermal leishmaniasis (PKDL), a sequel
to kala-azar mainly caused by Leishmania donovani is endemic in
the eastern part of India and the adjoining countries of Bangladesh
and Nepal. The importance of tracking this infection is vital for the
eradication of kala-azar. It is important to note that PKDL can occur
as long as 20 to 30 years after the episode of visceral infection.
The impact of adequate therapy of kala-azar on the occurrence of
PKDL remains unclear. The diverse clinical manifestations of PKDL
continue to evade clinicians. Unfortunately the recognition and
classiﬁcation of this dermatosis remains unsatisfactory. Traditional
methods like slit-skin smear and histopathology supplemented by
history are not sensitive since Leishman- Donovan bodies may not
be demonstrable in a signiﬁcant number. Immunohistochemical
and culture facilities are infrequently available and need exper-
tise. Recent studies have resorted to the use of rk39 strip test and
PCR/qPCR to conﬁrm the diagnosis. However the routine availabil-
ity of these tests needs much improvement even in the endemic
areas. Awareness of PKDL in non-endemic areas is to be increased
as kala-azar has also been reported from someof these places. Little
has been done to devise good therapeutic regimens to treat PKDL.
The antimony era proved very bad with gradually increasing doses
of parenteral antimony leading to a state where complications out-
ran beneﬁt. Further the development of antimony resistance ﬁnally
put an end to this era. Oral miltefosine made a breakthrough in
the beginning of this century and is currently the recommended
drug for this condition. The development of resistance and high
incidence of gastrointestinal side-effects following increased or
prolonged dosage are major deterrents. Trials are being conducted
with liposomal amphotericin to optimize the dose and duration in
PKDL. The greatest problems confronting clinicians in the use of
these two drugs, miltefosine and liposomal amphotericin, is the
availability, cost and hospitalization in case of the latter. Combi-
nation therapy is a powerful tool that has still to be explored. This
critical juncture when kala-azar appears to be on the wane signals
theneed for better drugs anddiagnostic facilities to effectively keep
PKDL under control.
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Combination treatment for visceral
leishmaniasis patients co-infected with human
immunodeﬁciency virus in India
S. Burza
Medecins Sans Frontieres, London, United Kingdom
Abstract: There are considerable numbers of patients co-
infected with Human Immunodeﬁciency Virus (HIV) and Visceral
Leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These
patients are at higher risk of relapse and death, but there are still
no evidence-based guidelines on how to treat them. In this study,
we report on treatment outcomes of co-infected patients up to 18
months following treatment with a combination regimen.
This retrospective analysis included all patients with conﬁrmed
HIV-VL co-infection receiving combination treatment for VL at an
MSF treatment centre between July 2012 and September 2014.
Patients were treated with 30 mg/kg body weight intravenous
liposomal amphotericin B (AmBisome®) divided as six equal dose
infusions combined with 14 days of 100 mg/day oral miltefosine
(Impavido®). All but eight patients started or were continued on
antiretroviral therapy (ART). Kaplan-Meier and proportional haz-
ard models were used to estimate cumulative incidence of death,
relapse, poor outcome (relapse and/or death) and associated risk
factors over an 18-month period following completion of treat-
ment.
102 patients (76% males, 57% with known HIV-infection, 54%
with a prior episode of VL) were followed-up for a median of
11 months (IQR:4-18). Median CD4-count at VL-diagnosis was
169 cells/L (IQR:88-230). Overall tolerance to treatment was
excellent. Sixteen patients died of whom 2 before completion of
treatment and 2 others after a VL relapse. Another 6 patients had a
VL relapse during the follow-up period. Cumulative incidence of
all-cause mortality and VL relapse at 6, 12 and 18 months was
11.7%, 14.5%, 16.6% and 2.5%, 6.0%,13.9% respectively. Cumulative
incidence of poor outcome at 6, 12 and 18monthswas 13.9%, 18.4%
and 27.2% respectively. Not initiating ART and concurrent tubercu-
losiswere independent risk factors formortality andpoor outcome.
No factors were associated with relapse.
In this study, combination therapy appeared to be well toler-
ated, safe and effective and may be considered as an option for
treatment of VL in HIV co-infected patients. Extended follow-up
and multidisciplinary management is critical. Evidence from ran-
domized clinical trials or larger prospective studies are essential to
establish optimal treatment regimens.
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